Featured Research

from universities, journals, and other organizations

Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit Prostate Cancer Patients

Date:
March 24, 2006
Source:
Cedars-Sinai Medical Center
Summary:
In a study to be published in the British Journal of Urology International, researchers at Cedars-Sinai Medical Center have shown that Raloxifene, a drug commonly used to treat osteoporosis, has a potential clinical benefit in treating men with prostate cancer. This study has implications for the approximately 35,000 men who will die this year of advanced prostate cancer.

In a study to be published in the April 2006 issue of the British Journal of Urology International, researchers at Cedars-Sinai Medical Center have shown that Raloxifene, a drug commonly used to treat osteoporosis, has a potential clinical benefit in treating men with prostate cancer. This study has implications for the approximately 35,000 men who will die this year of advanced prostate cancer.

Prostate cancer is the leading cause of cancer and the second leading cause of cancer-related death among men living in the United States. Approximately one in six men will be diagnosed with prostate cancer during his lifetime. "We undertook this study because we desperately need new therapies for patients with advanced prostate cancer," said David B. Agus, M.D., research director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai and principal investigator of the study.

Since Raloxifene is a drug already on the market, researchers were able to move directly into a Phase II clinical trial. They identified the presence of the beta isoform of the estrogen receptor in prostate cancer tissue samples, then moved directly into studies of animals with human prostate cancer, and then onto human clinical trials. The entire process took only 2-3 years.

"It used to be that to show effectiveness through research studies, cancer drugs needed to shrink tumors by 50 percent," Agus said. "Now, the new way of thinking about the effectiveness of cancer drugs is whether they can slow cancer's growth, which ultimately may significantly benefit patients."

Through the study, patients were given a daily oral dosage of Raloxifene, and the disease and its symptoms were followed on a regular basis. Some of the patients in the clinical trial taking Raloxifene showed evidence of disease stabilization manifested by a slowing or stopping of the growth of their prostate cancer.

According to Ronald L. Shazer, M.D., primary author of the manuscript, "The outcome from the Phase II clinical trial merits further study in a randomized clinical trial to demonstrate the clinical benefit of this targeted therapy."

The study was funded by the Prostate Cancer Foundation and the Elle and Paul Stephens Family Foundation.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Cedars-Sinai Medical Center. "Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit Prostate Cancer Patients." ScienceDaily. ScienceDaily, 24 March 2006. <www.sciencedaily.com/releases/2006/03/060322183458.htm>.
Cedars-Sinai Medical Center. (2006, March 24). Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit Prostate Cancer Patients. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2006/03/060322183458.htm
Cedars-Sinai Medical Center. "Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2006/03/060322183458.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Predicting Heart Transplant Rejection With a Blood Test

Predicting Heart Transplant Rejection With a Blood Test

Ivanhoe (Aug. 27, 2014) Now a new approach to rejection of donor organs could change the way doctors predict transplant rejection…without expensive, invasive procedures. Video provided by Ivanhoe
Powered by NewsLook.com
Better Braces That Vibrate

Better Braces That Vibrate

Ivanhoe (Aug. 27, 2014) The length of time you have to keep your braces on could be cut in half thanks to a new device that speeds up the process. Video provided by Ivanhoe
Powered by NewsLook.com
Smartphone App Tracks Your Heart Rate

Smartphone App Tracks Your Heart Rate

Ivanhoe (Aug. 27, 2014) A new app that can track your heart rate 24/7 is available for download in your app store and its convenience could save your life. Video provided by Ivanhoe
Powered by NewsLook.com
Stroke in Young Adults

Stroke in Young Adults

Ivanhoe (Aug. 27, 2014) A stroke can happen at any time and affect anyone regardless of age. This mother chose to give her son independence and continue to live a normal life after he had a stroke at 18 years old. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins